Gary Deutsch named chief of Division of Surgical Oncology at NYU Langone Hospital—Long Island

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Gary B. Deutsch

Gary B. Deutsch was named chief of NYU Grossman Long Island School of Medicine’s Division of Surgical Oncology. He was also named director of the hospital’s Robotic Surgical Oncology Program and professor in the school’s Department of Surgery. 

Deutsch comes to NYU Langone from Northwell Health. 

Deutsch has performed more than 500 complex robotic and minimally invasive surgeries in his career, consisting of innovative approaches to liver, pancreas, bile duct, and gastrointestinal malignancies. He was one of the first surgeons to perform a robotic Whipple procedure in New York and part of the first surgical team to perform a robotic prophylactic bilateral mastectomy in the United States.

“NYU Langone Hospital—Long Island is a special place. It has a long history and great local reputation,” Deutsch said in a statement. “I’m honored to join this team, known for its unbelievable quality of care and talent. The backing and funding for research and clinical innovation have elevated healthcare on Long Island to another level.”

Deutsch currently specializes in robotic hepatobiliary and pancreatic surgery, and sees patients at Perlmutter Cancer Center at NYU Langone Long Island Surgical Oncology Associates in Mineola. Some of his most important research activities include grant-funded research in robotic surgery performance assessment and in national cancer clinical trials. He has presented his work at international conferences, including the American College of Surgeons Surgical Forum.

As the chief of surgical oncology at the Perlmutter Cancer Center at NYU Langone Hospital—Long Island,  Deutsch will collaborate with leadership across clinical service lines—including hematology and medical oncology, gastroenterology, radiology, gynecologic oncology, and radiation oncology—to create a seamless network of care for patients from diagnosis to surgery and recovery. His core mission is to increase cancer patients’ quality of life during treatment using innovative therapies with fewer and more manageable side effects and more precise surgeries with shorter recovery times, all while offering the world-class care NYU Langone is known for at convenient locations for Long Island patients.

Table of Contents

YOU MAY BE INTERESTED IN

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login